Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$7.41
+21.9%		$6.77
$5.50
▼
$24.17
$210.62M2.39494,825 shs1.46 million shs
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$23.52
+0.9%		$20.24
$16.01
▼
$44.77
$45.05B0.57231,887 shs155,773 shs
Novartis AG stock logo
NVS
Novartis
$156.38
+1.4%		$152.99
$115.75
▼
$170.46
$298.30B0.451.72 million shs1.31 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.00%+28.65%+3.49%-19.63%-39.31%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.00%+8.66%+7.13%+8.31%-73.14%
Novartis AG stock logo
NVS
Novartis
0.00%+0.13%+1.09%+7.12%+37.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$7.41
+21.9%		$6.77
$5.50
▼
$24.17
$210.62M2.39494,825 shs1.46 million shs
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$23.52
+0.9%		$20.24
$16.01
▼
$44.77
$45.05B0.57231,887 shs155,773 shs
Novartis AG stock logo
NVS
Novartis
$156.38
+1.4%		$152.99
$115.75
▼
$170.46
$298.30B0.451.72 million shs1.31 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.00%+28.65%+3.49%-19.63%-39.31%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.00%+8.66%+7.13%+8.31%-73.14%
Novartis AG stock logo
NVS
Novartis
0.00%+0.13%+1.09%+7.12%+37.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
2.64
Moderate Buy$24.25227.26% Upside
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
1.80
ReduceN/AN/A
Novartis AG stock logo
NVS
Novartis
2.31
Hold$141.20-9.71% Downside

Current Analyst Ratings Breakdown

Latest CSLLY, NVS, and ARCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Novartis AG stock logo
NVS
Novartis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy (B)
7/22/2026
Novartis AG stock logo
NVS
Novartis
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
5/29/2026
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/11/2026
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/11/2026
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
5/11/2026
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$82.03M2.57N/AN/A$7.53 per share0.98
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$15.56B2.90$2.19 per share10.75$11.05 per share2.13
Novartis AG stock logo
NVS
Novartis
$54.53B5.47$10.74 per share14.56$22.04 per share7.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$65.78M-$2.81N/AN/AN/A-317.62%-46.54%-36.46%N/A
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$3.00BN/AN/A14.88N/AN/AN/AN/A8/17/2026 (Estimated)
Novartis AG stock logo
NVS
Novartis
$13.98B$6.6323.5915.942.6723.29%38.56%14.47%10/27/2026 (Estimated)

Latest CSLLY, NVS, and ARCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$0.9964-$0.84+$0.1564-$0.84$3.11 million$2.96 million
7/21/2026Q2 2026
Novartis AG stock logo
NVS
Novartis
$2.17$2.41+$0.24$1.71$14.07 billion$14.41 billion
6/30/2026Q2 2026
Novartis AG stock logo
NVS
Novartis
N/A$2.41N/A$1.71N/A$14.95 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/AN/AN/AN/AN/A
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$0.592.51%N/AN/AN/A
Novartis AG stock logo
NVS
Novartis
$3.081.97%+5.28%46.46%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/A
5.88
5.88
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.51
2.57
1.15
Novartis AG stock logo
NVS
Novartis
0.89
0.86
0.67

Institutional Ownership

CompanyInstitutional Ownership
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.03%
Novartis AG stock logo
NVS
Novartis
13.12%

Insider Ownership

CompanyInsider Ownership
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
17.80%
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
N/A
Novartis AG stock logo
NVS
Novartis
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18028.42 million23.36 millionOptionable
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
29,9041.92 billionN/ANot Optionable
Novartis AG stock logo
NVS
Novartis
75,2671.91 billion1.91 billionOptionable

Recent News About These Companies

Novartis AG Sponsored ADR
August 9 at 8:47 AM  |  cnn.comhttps://www.cnn.com/markets/stocks/NVS
Zacks Research Comments on Novartis' Q3 Earnings (NYSE:NVS)
August 7 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30945193
The Manufacturers Life Insurance Company Sells 24,216 Shares of Novartis AG $NVS
August 6 at 4:48 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-sells-24216-shares-of-novartis-ag-nvs-2026-08-06/
Research Analysts Offer Predictions for Novartis Q3 Earnings
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/research-analysts-offer-predictions-for-novartis-q3-earnings-2026-08-05/
Segall Bryant & Hamill LLC Purchases Shares of 18,792 Novartis AG $NVS
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-segall-bryant-hamill-llc-purchases-shares-of-18792-novartis-ag-nvs-2026-08-05/
Glenmede Trust Co. NA Acquires 8,680 Shares of Novartis AG $NVS
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-glenmede-trust-co-na-acquires-8680-shares-of-novartis-ag-nvs-2026-08-04/
FDA approval nearly doubles eligible patient pool for Novartis' Pluvicto
August 3, 2026  |  msn.comhttps://www.msn.com/en-us/health/general/fda-approval-nearly-doubles-eligible-patient-pool-for-novartis-pluvicto/ar-AA29jTUP
Novartis AG $NVS Shares Sold by Public Employees Retirement System of Ohio
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-sold-by-public-employees-retirement-system-of-ohio-2026-08-03/
Henshaw Capital LLC Grows Stock Position in Novartis AG $NVS
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-henshaw-capital-llc-grows-stock-position-in-novartis-ag-nvs-2026-08-02/
FY2026 EPS Estimates for Novartis Raised by Erste Group Bank
August 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30935315
Novartis AG $NVS Shares Purchased by Royal Bank of Canada
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-purchased-by-royal-bank-of-canada-2026-08-01/
Bank of America Corp DE Raises Stock Holdings in Novartis AG $NVS
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-raises-stock-holdings-in-novartis-ag-nvs-2026-08-01/
Erste Group Bank Forecasts Increased Earnings for Novartis
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/erste-group-bank-forecasts-increased-earnings-for-novartis-2026-07-31/
Novartis AG $NVS Shares Bought by Janus Henderson Group PLC
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-bought-by-janus-henderson-group-plc-2026-07-31/
Novartis AG $NVS Shares Bought by Empowered Funds LLC
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-bought-by-empowered-funds-llc-2026-07-31/
Arrowstreet Capital Limited Partnership Sells 679,380 Shares of Novartis AG $NVS
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-arrowstreet-capital-limited-partnership-sells-679380-shares-of-novartis-ag-nvs-2026-07-31/
Analysts Offer Insights on Healthcare Companies: Novartis (NVS) and NeoGenomics (NEO)
July 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NVS-N/pressreleases/3547501/analysts-offer-insights-on-healthcare-companies-novartis-nvs-and-neogenomics-neo/
Quantinno Capital Management LP Acquires 39,537 Shares of Novartis AG $NVS
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-acquires-39537-shares-of-novartis-ag-nvs-2026-07-30/
Ashton Thomas Securities LLC Makes New Investment in Novartis AG $NVS
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ashton-thomas-securities-llc-makes-new-investment-in-novartis-ag-nvs-2026-07-30/
Novartis chart may soon 'complete a well-defined bullish reversal,' Cappelleri says
July 29, 2026  |  cnbc.comhttps://www.cnbc.com/2026/07/29/novartis-chart-may-soon-complete-a-well-defined-bullish-reversal.html
Novartis AG (NYSE:NVS) Given Average Recommendation of "Hold" by Brokerages
July 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30928217

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$7.41 +1.33 (+21.88%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$7.37 -0.04 (-0.54%)
As of 08/7/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

CSL stock logo

CSL OTCMKTS:CSLLY

$23.52 +0.22 (+0.92%)
As of 08/7/2026 03:58 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Novartis stock logo

Novartis NYSE:NVS

$156.38 +2.17 (+1.41%)
Closing price 08/7/2026 03:59 PM Eastern
Extended Trading
$157.75 +1.37 (+0.87%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas